<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856904</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.202395</org_study_id>
    <secondary_id>2020-006050-51</secondary_id>
    <nct_id>NCT04856904</nct_id>
  </id_info>
  <brief_title>Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation</brief_title>
  <acronym>START</acronym>
  <official_title>Evaluation of the Risk of Atrophic Acne Scar Formation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 μg/g Cream Versus Vehicle Cream Over 24 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram&#xD;
      per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne&#xD;
      scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars&#xD;
      count.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change from Baseline in Total Atrophic Acne Scar Count Per Half-Face to Week 20</measure>
    <time_frame>Baseline upto Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Atrophic Acne Scar Count Per Half-Face From Baseline to Week 24</measure>
    <time_frame>Baseline upto Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Trifarotene Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trifarotene (CD5789) 50 mcg/g Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifarotene Cream</intervention_name>
    <description>Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks</description>
    <arm_group_label>Trifarotene (CD5789) 50 mcg/g Cream</arm_group_label>
    <other_name>AKLIEF®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifarotene Vehicle Cream</intervention_name>
    <description>Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks</description>
    <arm_group_label>Trifarotene Vehicle Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Participant with clinical diagnosis of acne vulgaris on the face as defined by&#xD;
             (excluding the nose and middle zone of approximately 2 centimeter [cm]):&#xD;
&#xD;
               1. Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe), with&#xD;
                  the same score on both sides of the face; and&#xD;
&#xD;
               2. A minimum of 20 inflammatory lesions (papules and pustules) in total with at&#xD;
                  least 10 on each side; and&#xD;
&#xD;
               3. No more than 2 nodules (greater than or equal to [&gt;=] 1 cm in diameter) on the&#xD;
                  face; and&#xD;
&#xD;
               4. A minimum of 10 atrophic acne scars in total (&gt;2 mm)&#xD;
&#xD;
          -  Participant with a symmetrical number of the following lesions/scars on the whole&#xD;
             face:&#xD;
&#xD;
               1. Inflammatory and non-inflammatory lesions; and&#xD;
&#xD;
               2. Atrophic acne scars (minimum of 4 scars per half-face)&#xD;
&#xD;
          -  The participant is a female of non-childbearing potential&#xD;
&#xD;
          -  If a female of childbearing, potential uses oral contraceptives that are also approve&#xD;
             for treating acne vulgaris&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne&#xD;
             and acne requiring systemic treatment&#xD;
&#xD;
          -  Participant with any acne cyst on the face or with more than 3 excoriated acne lesions&#xD;
&#xD;
          -  Participant with known active or chronic allergies or suspected allergy to trifarotene&#xD;
             or excipients of the formulation&#xD;
&#xD;
          -  Participant with facial dermal conditions (for example, tattoo, skin abrasion, eczema,&#xD;
             sunburned skin, scars, nevi, etc.) that may interfere with study assessments in the&#xD;
             opinion of the investigator&#xD;
&#xD;
          -  Participant with known impaired hepatic or renal functions, based on medical history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galderma Research &amp; Development</last_name>
    <phone>817-961-5000</phone>
    <email>clinical.studies@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Galderma Investigational Site #8873</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8447</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8608</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #9928</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8295</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8883</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8189</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8367</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8838</name>
      <address>
        <city>Darien</city>
        <state>Illinois</state>
        <zip>60561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8601</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #9936</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8108</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8881</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #8886</name>
      <address>
        <city>Sugarloaf</city>
        <state>Pennsylvania</state>
        <zip>18249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #9920</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #9918</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #9927</name>
      <address>
        <city>Saint-Jérôme</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site #6167</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne vulgaris</keyword>
  <keyword>Trifarotene</keyword>
  <keyword>AKLIEF®</keyword>
  <keyword>CD5789</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

